Use of dietary fibres against muscle wasting

Patent metadata

Field	Value
Publication number	US-9555059-B2
Application number	US-201213411227-A
Country	US
Kind code	B2
Filing date	Mar 2, 2012
Priority date	Dec 16, 2005
Publication date	Jan 31, 2017
Grant date	Jan 31, 2017

Abstract

A composition nutritional containing dietary fibers is useful for the treatment of muscle wasting, if the dietary fiber comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides, especially polysaccharides having a majority of anhydrofuranose units.

First claim

The invention claimed is:

1. A method for the treatment of muscle wasting and/or chronic muscle wasting and/or sarcopenia, the method comprising administering to a patient suffering from muscle wasting, chronic muscle wasting and/or sarcopenia a nutritional composition comprising dietary fibre, wherein the dietary fiber comprises at least 30 wt. % of galactooligosaccharides having a chain length of 3-10 anhydromonose units and having a majority of anhydropyranose units.

2. The method according to claim 1 , wherein the anhydropyranose units are selected from the group of galactose, mannose, xylose, their deoxy forms, amino forms and N-acylamino forms.

3. The method according to claim 1 , wherein the dietary fibre comprises 30-96 wt. % of oligosaccharides in which the anhydromonose units have a majority of anhydro-galactose units and 4-50 wt. % of oligosaccharides and/or polysaccharides in which the anhydro-monose units have a majority of anhydrofructose units.

4. The method according to claim 1 , wherein the dietary fibre comprises 50 to 100 wt % of the oligosaccharides having a chain length of 3-10 anhydromonose units.

5. The method according to claim 4 , wherein the dietary fibre comprises 70 to 98 wt. % of the oligosaccharides having a chain length of 3-10 anhydromonose units.

6. The method according to claim 1 , wherein the muscle wasting is associated with surgery, a trauma or inflammation.

7. The method according to claim 1 , wherein the nutritional composition further comprises digestible carbohydrates, fats, proteins or a combination thereof.

8. The method according to claim 7 , wherein the nutritional composition further comprises digestible carbohydrates, and the digestible carbohydrates comprise 20-80 wt. % of low-glycemic index and/or low-sweetness sugars selected from galactose, mannose, lactose, trehalose, palatinose and isomalto-oligosaccharides.

9. The method according to claim 1 , wherein the nutritional composition is a liquid composition having a viscosity of less than 35 Mpa·s at a shear rate of 100 sec −1 at 20° C.

10. The method according to claim 1 , wherein the nutritional composition has an energy density between 5.0 and 16.8 kJ/ml (1.2 and 4.0 kcal/ml).

11. The method according to claim 1 , wherein the nutritional composition has an energy density between 5.4 and 8.4 KJ/ml (1.3 and 2.0 kcal/ml).

12. The method according to claim 1 , wherein the composition further comprises a component supporting nucleotide synthesis and folate metabolism.

13. The method according to claim 12 , wherein the component supporting nucleotide synthesis and folate metabolism is folate in an amount of 50-1000 μg per g of fibre composition.

14. The method according to claim 1 , wherein the composition further comprises a carbohydrate fraction having a glycemic index of less than 70% the glycemic index of glucose.

15. The method according to claim 1 , comprising administering to a patient suffering from sarcopenia the nutritional composition.

16. The method according to claim 1 , wherein the dietary fiber further comprises fructopolysaccharides or inulin.

17. The method according to claim 7 , wherein the composition comprises 48-70 wt % essential amino acids.

Assignees

• Gorselink Marchel
• Van Helvoort Adrianus Lambertus Bertholdus
• Hageman Robert Johan Joseph
• Nutricia Nv

Inventors

• Gorselink Marchel
• Van Helvoort Adrianus Lambertus Bertholdus
• Hageman Robert Johan Joseph

Classifications

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P3/02

  Nutrients, e.g. vitamins, minerals · CPC title

• A61P21/06

  Anabolic agents (androgens A61P5/26) · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title

• A61K31/702

  Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title